Advertisement
ResearchIn-Press PreviewImmunologyOncology
Open Access |
10.1172/JCI193945
1Cancer Center, Huazhong University of Science and Technology, Wuhan, China
2Department of Radiation Oncology, Hangzhou Medical College, Hangzhou, China
Find articles by Deng, Y. in: PubMed | Google Scholar
1Cancer Center, Huazhong University of Science and Technology, Wuhan, China
2Department of Radiation Oncology, Hangzhou Medical College, Hangzhou, China
Find articles by Liu, X. in: PubMed | Google Scholar
1Cancer Center, Huazhong University of Science and Technology, Wuhan, China
2Department of Radiation Oncology, Hangzhou Medical College, Hangzhou, China
Find articles by Yang, X. in: PubMed | Google Scholar
1Cancer Center, Huazhong University of Science and Technology, Wuhan, China
2Department of Radiation Oncology, Hangzhou Medical College, Hangzhou, China
Find articles by Wei, W. in: PubMed | Google Scholar
1Cancer Center, Huazhong University of Science and Technology, Wuhan, China
2Department of Radiation Oncology, Hangzhou Medical College, Hangzhou, China
Find articles by Wang, J. in: PubMed | Google Scholar
1Cancer Center, Huazhong University of Science and Technology, Wuhan, China
2Department of Radiation Oncology, Hangzhou Medical College, Hangzhou, China
Find articles by Yang, Z. in: PubMed | Google Scholar
1Cancer Center, Huazhong University of Science and Technology, Wuhan, China
2Department of Radiation Oncology, Hangzhou Medical College, Hangzhou, China
Find articles by Sun, Y. in: PubMed | Google Scholar
1Cancer Center, Huazhong University of Science and Technology, Wuhan, China
2Department of Radiation Oncology, Hangzhou Medical College, Hangzhou, China
Find articles by Hu, Y. in: PubMed | Google Scholar
1Cancer Center, Huazhong University of Science and Technology, Wuhan, China
2Department of Radiation Oncology, Hangzhou Medical College, Hangzhou, China
Find articles by Zhang, H. in: PubMed | Google Scholar
1Cancer Center, Huazhong University of Science and Technology, Wuhan, China
2Department of Radiation Oncology, Hangzhou Medical College, Hangzhou, China
Find articles by Wang, Y. in: PubMed | Google Scholar
1Cancer Center, Huazhong University of Science and Technology, Wuhan, China
2Department of Radiation Oncology, Hangzhou Medical College, Hangzhou, China
Find articles by Zhang, Z. in: PubMed | Google Scholar
1Cancer Center, Huazhong University of Science and Technology, Wuhan, China
2Department of Radiation Oncology, Hangzhou Medical College, Hangzhou, China
Find articles by Wen, L. in: PubMed | Google Scholar
1Cancer Center, Huazhong University of Science and Technology, Wuhan, China
2Department of Radiation Oncology, Hangzhou Medical College, Hangzhou, China
Find articles by Huang, F. in: PubMed | Google Scholar
1Cancer Center, Huazhong University of Science and Technology, Wuhan, China
2Department of Radiation Oncology, Hangzhou Medical College, Hangzhou, China
Find articles by Yang, K. in: PubMed | Google Scholar
1Cancer Center, Huazhong University of Science and Technology, Wuhan, China
2Department of Radiation Oncology, Hangzhou Medical College, Hangzhou, China
Find articles by
Wan, C.
in:
PubMed
|
Google Scholar
|
Published October 7, 2025 - More info
The immunosuppressive tumor microenvironment (TME) drives radioresistance, but the role of γδ T cells in regulating radiosensitivity remains incompletely understood. In this study, we found that γδ T cell infiltration in the TME substantially increased after radiotherapy and contributed to radioresistance. Depletion of γδ T cells enhanced radiosensitivity. Single-cell RNA sequencing revealed that γδ T cells in the post-radiotherapy TME were characterized by the expression of Zbtb16, Il23r, and Il17a, and served as the primary source of IL-17A. These γδ T cells promoted radioresistance by recruiting myeloid-derived suppressor cells and suppressing T cell activation. Mechanistically, radiotherapy-induced tumor cell-derived microparticles containing dsDNA activated the cGAS-STING/NF-κB signaling pathway in macrophages, upregulating the expression of the chemokine CCL20, which was critical for γδ T cell recruitment. Targeting γδ T cells and IL-17A enhanced radiosensitivity and improved the efficacy of radiotherapy combined with anti-PD-1 immunotherapy, providing potential therapeutic strategies to overcome radioresistance.